We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
The intrigue of ASX growth shares enthrals many investors. Often, stocks in this category catch head...
Read ArticleHighlights ASX200 falls 0.57% after touching a record high near 8,400 points. Health Care s...
Read ArticleASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7% Neuren s...
Read ArticleThe best ASX shares in terms of share price gains since the US election make for interesting reading...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) managed to s...
Read ArticleThree ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12%...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) endured anothe...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decline. A...
Read ArticleThe market may be nearing a record high, but that doesn't mean there aren't big potential gains to b...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) enjoyed an enthu...
Read ArticleHighlights ASX gains on Fed rate cuts and China's potential stimulus. Life360 and Commonwealth...
Read ArticleHighlights S&P/ASX 200 rises on global rate cuts and China stimulus hopes. Tech and ban...
Read ArticleASX rallies broadly as tech stocks lead Commonwealth Bank hits record, Neuren jumps Asian markets r...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a great finish to the week. In afternoon trade, the...
Read ArticleIt was a wild session for the S&P/ASX 200 Index (A...
Read ArticleASX slipped after early gains, then finished strongly Energy sector helped offset losses; Quickste...
Read ArticleHighlights ASX gains slightly, led by energy and mining sectors on China stimulus hopes. Ban...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has failed to follow Wall Street's stunning lead and has dropp...
Read ArticleHighlights ASX edges lower due to declines in property sector despite gains in other sectors....
Read ArticleHighlights Australian shares dip as miners and banks retreat post-U.S. election. Notable drops...
Read ArticleHaving pocketed a US$50 million share of an FDA priority review voucher, Neuren reports bumper resu...
Read ArticleThis article is part of the daily news updates from FNArena.com. Stay informed with the latest finan...
Read ArticleThe ASX200 has been up 0.83% at 8199 points. Counting in the US election continues and markets ar...
Read ArticleNeuren Pharmaceuticals (ASX: NEU), a Melbourne-based biotech that is developing therapies for neurod...
Read ArticleASX healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has surged in early trade on Wednesday af...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) is set to receive a substantial payout following the sale of a Rare...
Read ArticleAre you on the hunt for big returns to supercharge your portfolio? If you are, then it could pay to...
Read ArticleLooking for big returns to supercharge your investment portfolio? If you are, it could be worth chec...
Read ArticleWhat’s in a name? Not much, according to the CEO of the now cashed-up Percheron, Dr James Garner. Fo...
Read ArticleThe ASX200 closed up around 0.9% at 8,355 points after hitting a new record of 8,384 points just bef...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At t...
Read ArticleThe Australian share market is rebounding nicely on Thursday following a solid session on Wall Stree...
Read ArticleNyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharm...
Read ArticleJon Pilcher – Managing Director & CEO – Neuren Pharmaceuticals Limited (ASX:NEU) is developing...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is fighting hard to get into positive ter...
Read ArticleThe ASX200 has been up around 0.6% of a percent at 8,198 points in early afternoon trade. The lab...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At t...
Read ArticleNeuren Pharmaceuticals Ltd (ASX: NEU) shares are having a strong start to the week. In morning trade...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has said it’s received a “positive” response from the FDA regarding...
Read ArticleIf you are looking for some new additions to your portfolio in October, then the ASX shares listed b...
Read ArticleIt was a bouncy, yet overall positive day for ASX shar...
Read ArticleStockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) may be at a record high, but that doesn't mean there aren't an...
Read ArticleWhen I last covered ImpediMed (ASX:IPD) in May last year, I opined that the time-honoured way of lif...
Read ArticleAre you wanting big returns for your portfolio? Then look no further! That's because the ASX 200 sha...
Read ArticleAustralia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to M...
Read Article4DMedical could replicate Pro Medicus’ US success Its new tech could revolutionise lung disease dia...
Read ArticleDimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involv...
Read ArticleThis article is part of the daily news updates from FNArena.com. Stay informed with the latest finan...
Read ArticleASX healthcare stocks showed mixed results following the release of their most recent financials on...
Read ArticleYou'll find that not everyone's definition of top ASX stocks is the same. Some investors prefer lowe...
Read ArticleASX health stocks rise 0.8% past five days as broader market lifts 3.7% Morgans says ProMedicus ‘p...
Read ArticleNeurotech to secure one or more strategic partnerships for NTI164 in the US, Europe and Asia Partne...
Read ArticleThe Australian Securities Exchange (ASX) has started this week on a much more positive note compared...
Read ArticleThe ASX200 closed up 1.25% at 7777.7 points, completing the second green session in a row. It has...
Read ArticleWhile the S&P/ASX 200 Index (ASX: XJO) is enjoying a strong session on Friday, up 1.45% to 7,792...
Read ArticleThe Australian Securities Exchange (ASX) has rounded out a volatile week in the positive, with the S...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a very pos...
Read ArticleNeuren (ASX:NEU) was the biggest faller in lunchtime trades on Friday after announcing some children...
Read ArticleNeuren shows promise in Angelman drug but shares down 7pc Avita aims for profitability by Q3 FY25 I...
Read ArticleNeuren Pharmaceuticals Ltd (ASX: NEU) shares have returned from their trading halt with an almighty...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) comprises 11 market sectors, and the outperformer over the p...
Read ArticleWith recent market volatility, prudent investors in ASX shares may be finding some relief. The uncer...
Read ArticlePrudent investors in ASX shares will no doubt be breathing easier on Wednesday following the recent...
Read ArticleAs the market whipsaws away this week, one ASX 200 healthcare share is on ice on Wednesday. Neur...
Read ArticleIf you want to give your portfolio a boost, then it could be worth looking at Neuren Pharmaceuticals...
Read ArticleRecent evaluations have spotlighted three ASX 200 shares that present notable opportunities for inve...
Read ArticleBrokers have been running the rule over a large number of ASX 200 shares in recent weeks. Three shar...
Read ArticleNeurotech reports positive results from extension phase of Phase 1/2 trial of NTI164 to treat Ret...
Read ArticleASX health stocks rise 2% in past five days as broader markets lift 0.6% Morgans upgrades disinfect...
Read ArticleNeuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Pr...
Read ArticleNeuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Pr...
Read ArticleFollowing Monday's market euphoria and fresh all-time highs, it was only natural for the S&P/ASX...
Read ArticleThe 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference l...
Read ArticleFortunately for growth investors, there are a lot of quality options for them to choose from on the...
Read ArticleIf you were invested in ASX 200 shares vs. property in FY24 then you probably did pretty well. T...
Read ArticleIf you're in the market for some new ASX 200 shares in July, then it could be worth listening to wha...
Read ArticleIn this article, we examine the best ASX 200 healthcare shares of FY24 based on share price growth....
Read ArticleWhen we compare the capital growth of ASX 200 shares vs. property in FY24, bricks and mortar comes o...
Read ArticleIf you are lucky enough to have $10,000 burning a hole in your pocket, it could be worth putting it...
Read ArticleA new financial year is on the horizon, so what better time to make some new additions to your inves...
Read ArticleASX health stocks rise in past five days, despite May uptick in inflation Healius downgrades guida...
Read ArticleI joined Adam Keily on the ‘Equity Mates’ podcast to discuss eight small-cap stocks, share my insigh...
Read ArticleVinay Ranjan from Airlie Funds Management says investors should ignore industry predictions for wher...
Read ArticleASX 200 healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has posted impressive gains over the...
Read ArticleLooking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceutical...
Read ArticleASX health stocks fall in past five days in line with broader markets as investors spooked by hotte...
Read ArticleIf you want to give your investment portfolio a nice boost, then it could be worth considering the A...
Read ArticleThe ASX200 didn’t seem to be able to recover from the CPI inflation data (April) read – showing a ri...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a very tough session on Wednesday. In response to th...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has reported positive results from a Phase 2 trial of NNZ-2...
Read ArticleASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial r...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price was in fine form on Monday. The ASX 200 pharma...
Read ArticleOn Monday, the S&P/ASX 200 Index (ASX: XJO) started the week in a very positive fashion. The be...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) enjoyed a strong st...
Read ArticleASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Str...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a strong start to the week. In afternoon trade, the...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200  healthcare...
Read ArticleLast Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of R...
Read ArticleXero and Nvidia buoyed Tech, while BHP dragged Mining Gold stocks were the worst performing miners...
Read ArticleOne of the highest growth ASX 200 healthcare stocks on the market went into a trading halt on Thursd...
Read ArticleDo you remember how the COVID-19 market crash began, with ASX 200 shares plummeting almost 700 point...
Read ArticleI really like being gifted the data drops every month or so from the growing family of madly conveni...
Read Article“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Austral...
Read ArticleASX gained on the aftermath of Budget Silver stocks on a roll, along with other miners Market newbi...
Read ArticleASX retreats on Tuesday ahead of Fed Budget and US PPI/CPI Copper stocks up after the metal hit hig...
Read ArticleFour S&P/ASX 300 Index (ASX: XKO) shares were just re-rated by top brokers. One operates in the...
Read ArticleASX health stock rise in past five days along with broader markets Wound care company Polynovo ac...
Read ArticleIt has been another busy week for Australia's top brokers. This has led to the release of a number o...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has returned to form on Friday. In afternoon trade, the benchma...
Read ArticleImricor has two upcoming pivotal trials and is looking to transform cardiac ablation procedures Bo...
Read ArticleASX losses accelerate after sluggish retail sector updates Baby Bunting, Temple & Webster, JB...
Read ArticleIt was the ASX 200 healthcare stock of the year in 2023, with its share price catapulting 214% in ju...
Read ArticleNeuren Pharma’s Q1 DAYBUE sales disappoint 4DMedical’s CT LVAS technology gets reimbursement in US...
Read ArticleNeurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improve...
Read ArticleShare tips and stock recommendations for the Australian (ASX) share market – buy, hold, and sell. Mi...
Read ArticleTurning $100,000 into a million bucks might sound like magic. But no one needs supernatural powers...
Read ArticleIf you've been a bunny and missed out on the 3.45% gains already delivered by the S&P/ASX 200 I...
Read ArticleWhen an S&P/ASX 200 Index (ASX: XJO) stock outperforms all and sundry one year but then suddenl...
Read ArticleThe green graphics card giant is making a motza. But did you know some ASX companies have even bigg...
Read ArticleMany Australians have the impression that investing in stocks is only for rich people. But that ca...
Read ArticleMorgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle...
Read ArticleIf you have $10,000 to invest right now, there are some excellent S&P/ASX 200 Index (ASX: XJO)...
Read ArticleTim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter wh...
Read ArticleThe Insurance Australia Group Ltd (ASX: IAG) interim dividend announced last month was 67% higher t...
Read ArticleNyrada jumped 400pc in a single day last month The company reported good results from its Brain Inj...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) might have risen four months straight, but many experts are st...
Read ArticleWith so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The...
Read ArticleWelcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AUA...
Read ArticleWith earnings season nearing an end, we showcase 12 ASX shares that delivered some of the best prof...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price gained 1.1% to close at $19.36 on Thursday d...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has reported highlights from the fourth quarter 2023 earnin...
Read ArticleThe ASX200 closed flat despite futures having tipped a moderate green day on market as investors end...
Read ArticleLithium miners surge NextDC also jumps on strong H1, but Flight Centre tumbles Aussie inflation low...
Read ArticleThe ASX200 has been trading quite flat. The IT sector has surged, up more than 2 per cent, while...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. A...
Read ArticleNeuren Pharmaceuticals Ltd (ASX: NEU) shares are crashing deep into the red today. At one stage tod...
Read ArticleNeuren’s Daybue sales meet target Proteomics granted patent in Europe Nyrada’s brain injury drug...
Read ArticleNeuren has reported over US$87M in sales of DAYBUE in Q4 of 2023 The drug is sold by NASDAQ-list...
Read ArticleOne in eight people in the world have some form of mental disorder TrivarX’s AI technology diagnose...
Read ArticleIf you want to receive the next Insurance Australia Group Ltd (ASX: IAG) dividend, then you will ha...
Read ArticleBiotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Sto...
Read ArticleWith so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The...
Read ArticleBy Greg Peel Resourceful The ASX200 shot up 76 points from the open on Friday on a combination of re...
Read ArticleOn Friday, the S&P/ASX 200 Index (ASX: XJO) ended the week with a solid gain. The benchmark in...
Read ArticleIt's funny to call an ASX stock that's rocketed 217% in the past year a "bargain". But that's preci...
Read ArticleASX adds 0.7pc to close out the week in a positive frame of mind IT and materials rise, thanks to...
Read ArticleASX health sector falls broader market with some key names ailing in reporting season CSL Phase III...
Read ArticleIt has been another busy week for Australia's top brokers. This has led to the release of a number...
Read ArticleWe had a team meeting this morning. We were discussing how to make sure our readers and members wer...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) shares are tanking on news its US partner allegedly mischaracterise...
Read ArticleNeuren Pharmaceuticals Ltd (ASX: NEU) shares are ending the week deep in the red. The ASX 200 healt...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) was on form in November and charged higher. Over the period,...
Read ArticleASX health stocks flat in past five days in line with broader markets Avita lowers full year 2023...
Read ArticleASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing...
Read ArticleNeuren Pharmaceuticals Ltd (ASX: NEU) shares are having a positive start to the week. In afternoon...
Read ArticleOn Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a subdued note. The benchmar...
Read ArticleASX health stocks rise in past five days and outpace broader markets for second week All study visi...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleAt the $240 million Perennial Better Future Trust, healthcare stocks are a critical component of our...
Read ArticleAn additional news report on the recommendation, valuation, forecast and opinion changes and updates...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced that its Phase 2 clinical trial of NNZ-2591 f...
Read ArticleASX health stocks rise in past five days and outpace broader markets Blue chip ResMed slips as US F...
Read ArticleASX erased yesterday’s gains on Fed chair Powell’s hawkish tilt The RBA has revised its inflation t...
Read ArticleASX closed modestly higher as stocks were up across the board Xero slumped 13pc, despite delivering...
Read ArticleASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports re...
Read ArticleWe’re coming to you from Perth Town Hall, where the Young Investor Carnival has been held today....
Read ArticleASX lifted 1pc on Friday, up 3pc for the week Neuren, Block Inc, Lendlease, and media stocks were t...
Read ArticleNeuren Pharmaceuticals (ASX: NEU) is expecting to receive increasing royalty payments from its US pa...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a very po...
Read ArticleWelcome to our market update, coming to you from the Young Investor Carnival at the Perth Townhall t...
Read ArticleNeurotech has a clear path for development and commercialisation of NTI164 to treat PANDAS/PANS W...
Read ArticleNeuren’s blockbuster drug DAYBUE generates big sales in Q3 Argenica jumps 40pc after releasing prec...
Read ArticleASX-listed Impedimed Limited Pharmaceuticals (ASX:IDP), Avita Medical (ASX:AVH), and Neuren...
Read ArticleAsk any chief of a development-stage biotech about the prospect of a partnering or licencing deal an...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is in fine form on Tuesday. In afternoon trade, the benchmar...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has fin...
Read ArticleASX closes higher as Wall Street rebounds and US bond yields retreat on weaker jobs data Lithium mi...
Read ArticleIf you're in the market for some new ASX shares this month, then it could be worth listening to wha...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has just...
Read ArticleASX slips to 100-day low as climbing US 10-year bond yields weigh on global markets RBA keeps rates...
Read ArticleWith apologies to Charles Dickens, it’s the best of times and the worst of times for wound care hous...
Read ArticleIt's been yet another day of falls for ASX share...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has once aga...
Read ArticleASX health sector falls in line with broader markets as macroeconomic factors continue to create un...
Read Article2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead t...
Read ArticleHere’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 2...
Read ArticleIt's been another sad day for the S&P/ASX 200 Inde...
Read ArticleSeveral ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their...
Read ArticleFor me, earnings without guidance is a bit like pizza without cheese – little more than cooked tomat...
Read ArticleASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Cli...
Read ArticleHarvey Norman booted out of S&P ASX 100 as lithium play Liontown Resources admitted 2023 market...
Read ArticleItâs that time of the year again when S&P Dow Jones Indices announces the rebalance of the S&...
Read ArticleASX health sector rises in line with broader markets as reporting season comes to end EBR Systems o...
Read ArticleWelcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AGI...
Read ArticleASX healthcare stocks haven’t done so well as a collective over the past 12 months. The S&P/AS...
Read ArticleNeuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year Eye...
Read ArticleMoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We...
Read ArticleMoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and...
Read ArticleASX health stocks fall 1.82% in the past five days in line as broader markets rise slightly Resmed...
Read ArticleASX health stocks up 1% in the past five days in line with broader markets Volpara records third qu...
Read ArticleASX 200 climbed to a 100-day high Energy and Mining retreated after a flurry of earnings reports F...
Read ArticleASX-listed AusBiotech member Neuren Pharmaceuticals (ASX:NEU) has received the Blake Award f...
Read ArticleThe ASX 200 built a platform for success today. Which failed. It fell flat at close Sectors wise, F...
Read ArticleThese are the stories that are the stuff of dreams for every single ASX All Ords shares investor. B...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decline. At the...
Read ArticleNeurotech is following in the footsteps of 2023 market darling of the ASX biotech sector Neuren with...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced the global expansion of its partnership with...
Read ArticleThe ASX will open flattish as Wall Street finished modestly lower on Friday US banks were mixed fol...
Read ArticleASX health stocks fall in past five days with Power noting larger names trading on attractive valu...
Read ArticleJunior biotech Neuren Pharmaceuticals has signed an expanded licensing deal with its US distributio...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a high. A...
Read ArticleASIC plans to establish a stakeholder advisory group to oversee ASX's troubled CHESS replacement pro...
Read ArticleNeuren Pharma share price jumps after extending partnership deal with Acadia Acadia will now be the...
Read ArticleNeuren Pharmaceuticals (NEU) receives $145 million from its partner Acadia Pharmaceuticals to expand...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) announced the expansion of its partnership with Acadia Pharmaceut...
Read ArticleMagnis Energy Technologies Ltd (ASX: MNS) shares wonât be going anywhere again on Friday. Thatâ...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price is on course to end the week on a very positi...
Read ArticleAustralian shares are set to open in the green after tech stocks rallied strong trade on Wall Street...
Read Article14 Jul 2023 - A snapshot of the stocks on the move, featuring Neuren Pharmaceuticals (ASX:NEU), Gree...
Read ArticleASX health stocks have fallen in the past five days in line with broader markets Mach7 wins a US$60...
Read ArticleASX All Ords shares closed out FY23 with a solid 8.85% gain but as shown in the chart below, it was...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced that the first site in the US for its Phase 2...
Read ArticleNeuren Pharmaceuticals (NEU) opens the first site in the United States for its phase two clinical tr...
Read ArticleRamsay Healthcare rises after announcing it is looking to sell its joint Asian venture Neuren annou...
Read ArticleAvita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will...
Read ArticleSigma offers very competitive terms to win back Chemist Warehouse contract from Rival EBOS Pacific...
Read ArticleAustralian company Neuren Pharmaceuticals (ASX:NEU) has received the US$40 million milestone...
Read ArticleBy Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m...
Read ArticleThe final day of the trading week saw the ASX finish in the green up 0.48 per cent. This comes af...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleA market analyst has outlined why three ASX shares are a buy in the eyes of the team at Bell Potter...
Read ArticleWall Street was closed for Memorial Day, European shares were slightly down Beware of “downside cor...
Read ArticleThe market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts...
Read ArticleEBR announces positive results of its pivotal SOLVE-CRT trial at Heart Rhythm 2023 in US EBR latest...
Read ArticleOrphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an e...
Read ArticleASX health stocks rise in the past five days in line with broader markets Immutep surges 46% after...
Read ArticleASX health stocks rise in the past five days outperforming broader markets Avita Medical product sa...
Read ArticleHave you ever wondered which ASX shares rich people have bought? Maybe you’d like to emulate their...
Read ArticleASX health stocks fall 0.8% in the past five days in line with broader markets following latest rat...
Read ArticleASX health stocks fall 0.32% in the past five days, despite rise in broader markets Neuren Pharmace...
Read ArticleAustralian company Neuren Pharmaceuticals (ASX:NEU) is set to receive a US$40 million milest...
Read ArticleShareCafeASX recoups some earlier losses to close 0.29% lower by Peter Milios At the closing bell,...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleThe ASX slumped by 0.4% today as the RBA released its April minutes Core Lithium jumped 8pc after i...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and on course to record a disappoint...
Read ArticleNeuren’s breakthrough drug DAYBUE starts selling in the US Orthocell commences nerve repair study...
Read ArticleThe leading investors from Wilson Asset Management (WAM) have shared thoughts on two ASX shares. WA...
Read ArticleInvestors on Stake have been turning to gold to position for market volatility as price of precious...
Read ArticleASX health stocks rise 0.97% in the past five days in line with broader markets Impedimed up 99% af...
Read ArticleSeveral ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix P...
Read ArticlePrescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive...
Read ArticleHealius gets takeover offer from ALC, a company more than half its size Neurotech will launch Phase...
Read ArticleSaturday March 11 was a typical balmy autumnal afternoon in Melbourne, but Neuren (ASX:NEU) chief Jo...
Read ArticleASX health stocks fall 1.5% in the past five days, broader markets fall on global banking concerns...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a small gain. In afternoon...
Read ArticleThe S&P/ASX 300 index may be trading notably lower than its recent highs, but that hasnât sto...
Read ArticleAmidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first a...
Read ArticleLocal shares bounced back on Wednesday following a strong rally in New York overnight Neuren was on...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) on course for a much-needed gain. At the...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price is racing higher again on Wednesday. In morni...
Read ArticleASX hammered as bank-driven fear grips the market like a python round a possum XEC Emerging Compani...
Read ArticleThe ASX fell 1.6% on Tuesday on concerns of a global meltdown following SVB’s collapse Gold stocks...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is out of form again on Tuesday. In afternoon trade, the bench...
Read ArticleA major win for Australian company Neuren Pharmaceuticals (ASX:NEU) with the US FDA approvin...
Read ArticleASX weathers a US bank collapse storm to finish the day down just 0.5% XEC Emerging Companies index...
Read ArticleShareCafeTech and Financials drag ASX 0.5% lower at the close by Peter Milios On Monday, the S&...
Read Article13 Mar 2023 - A snapshot of the stocks on the move featuring Neuren Pharmaceuticals (ASX:NEU), Metro...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. At the time of wri...
Read ArticleShareCafeASX down 0.61% at noon as SVB saga continues by Peter Milios The collapse of Silicon Vall...
Read ArticleShareCafeStocks of the Hour: NEU, MMI, MEI Neuren Pharmaceuticals (ASX:NEU)...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Melbourne-based Neuren Phar...
Read ArticleNeuren Pharma gets a ‘historic’ FDA approval for DAYBUE to treat Rett syndrome Genetic Technologies...
Read ArticleThe US Food and Drug Administration (FDA) approves Neuren Pharmaceuticals’ (NEU) North American part...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price is starting the week very positively. In morn...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleNeuren’s compound trofinetide has been granted US FDA approval for the treatment of Rett’s syndrome...
Read ArticleASX health stocks fall 1.87% in the past five days as reporting season ends Healius moves to a stat...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced the appointment of Joe Basile as an independe...
Read ArticleThe US FDA is expected to decide on March 12 whether it approves Neuren’s trofinetide for Rett’s sy...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has reviewed Neuren’s Investi...
Read ArticleCynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biote...
Read ArticleUniversal Bio completes patient recruiting for Xprecia Prime study Neuren Pharma given approval by...
Read ArticleNeuren Pharmaceuticals (NEU) receives the green light to go ahead with a phase two clinical trial te...
Read ArticleASX health stocks rise 4.6% this week with positive signs of being back in favour Volpara soars aft...
Read ArticleThe All Ordinaries Index (ASX: XAO) is back in the green on Wednesday, driven higher by four shares...
Read ArticleThe S&P/ASX 300 Index (ASX: XKO) is full of interesting businesses. A leading fund manager has...
Read Article2023 off to a bit of a dismal start, down 1.3% on the opening day of trade GreenX soaring after rum...
Read ArticleThe ASX tumbled over 1% in the first trading day of 2023 Stocks were sold across all sectors, with...
Read ArticleThe new year is off to a disastrous start for the All Ordinaries Index (ASX: XAO) and most of the s...
Read ArticleHighlights The ASX 200 benchmark index closed in the red today (December 28), losing 32.30 point...
Read ArticleGood news is bad news for the US economy Aussie benchmark goes deep into a pre-Christmas shame spir...
Read ArticleNeuren Pharmaceuticals (NEU) submits an investigational new drug (IND) application for its NNZ-2591...
Read ArticleWarrego Energy puts out initial substantial shareholder notice for Gina Rinehart entities following...
Read ArticleASX Health sector is continuing its upward trend, marginally up this week 0.87% Sonic Healthcare a...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleThe All Ordinaries Index (ASX: XAO) is kicking off this Tuesday’s session on a very positive note s...
Read ArticleThe All Ordinaries Index (ASX: XAO) is down in the dumps on Thursday. But not all shares that call...
Read ArticleNeuren Pharmaceuticals (NEU) receives a US$10 million (A$16 million) milestone payment from its part...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has received the milestone payment of US$10 million from it...
Read ArticleWelcome back class to Part 2 of our Clinical Trials 101. When it comes to healthcare and life scienc...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a day to forget on Wednesday. In afternoon trade,...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is on form again on Tuesday. In afternoon trade, the benchmar...
Read ArticleNeuren Pharmaceuticals (NEU) receives priority review for a New Drug Application (NDA) of its trofin...
Read ArticleActing out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxi...
Read ArticleThe All Ordinaries Index (ASX: XAO) has been in a pendulum swing over the ASX reporting season. Her...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced its Phase 2 clinical trials of NNZ-2591 in ch...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced its Phase 2 clinical trials of NNZ-2591 in ch...
Read ArticleHighlights Neuren Pharmaceuticals (ASX:NEU) has began recruiting subjects for Phase 2 clinical t...
Read ArticleHighlights Neuren Pharmaceuticals (ASX:NEU) has began recruiting subjects for Phase 2 clinical t...
Read ArticleAcrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commen...
Read ArticleNeuren Pharmaceuticals (NEU) opens enrolment for phase two neurological clinical trials of its drug...
Read ArticleHighlights: WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 c...
Read ArticleHighlights: WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 c...
Read ArticleHighlights The Australian share market ended on a positive note on Wednesday. The ASX 200...
Read ArticleHighlights The Australian share market ended on a positive note on Wednesday. The ASX 200...
Read ArticleThe All Ordinaries Index (ASX: XAO) is down a slender 0.04% in late afternoon trading, having made...
Read ArticleWhat are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up...
Read ArticleMoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We...
Read ArticleA major milestone for Australian company Neuren Pharmaceuticals (ASX:NEU) with its US partne...
Read ArticleNeuren Pharmaceuticals (NEU) submits a new drug application (NDA) to the US FDA for its Rett syndro...
Read ArticleHeraMED’s device is effective for telemedicine in monitoring pregnant women Mesoblast issues strong...
Read ArticleMach 7 announces patent infringement lawsuit settled in its favour Lumos Diagnostics tanks after d...
Read ArticleNeuren Pharmaceuticals (ASX: NEU) has announced that its Phase 2 clinical trial of NNZ-2591...
Read ArticleNeuren Pharmaceuticals (NEU) opens its Phase Two clinical trial of its NNZ-2591 drug in Angelman sy...
Read ArticleNeuren’s Phase 2 clinical trial is now open for enrolment Neuroscientific submits an ethics approva...
Read ArticleShareCafeEvening Report: 8 July, 2022 by Lauren Evans The Australian sharemarket had its best week...
Read ArticleNeuren Pharmaceuticals (NEU) appoints Liza A Squires to the new position of Chief Medical Officer i...
Read ArticleHighlights Firebrick secures patent in Malaysia for Nasodine® Nasal Spray as a treatment and pre...
Read ArticleHighlights The benchmark index ASX200 was 0.037% lower at 7146.200 points at 11:10 AM AEST today...
Read ArticleHighlights Neuren Pharmaceuticals focuses on developing new drug therapies for serious neurologi...
Read ArticleMegaport gets support of major investment firms increasing holdings Gold Road Resources increases s...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has received US FDA approval to proceed with the Phase 2 tr...
Read ArticleHighlights The Australian healthcare sector includes companies engaged in biotechnology and rese...
Read ArticleHighlights The benchmark ASX 200 was trading 0.15% up at 7,409.8 in the first 15 minutes of trad...
Read ArticleNeuren Pharmaceuticals (NEU) has approval from the US Food and Drug Administration (FDA) to proceed...
Read ArticleNeuren Pharmaceuticals (NEU) receives the all clear from the US Food and Drug Administration (FDA)...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced it has received approval from the Human Resea...
Read ArticleNeuren Pharmaceuticals (NEU) is granted ethics approval to move ahead with its phase two clinical t...
Read ArticleHighlights Several ASX stocks have returned over 100% to shareholders in the past year. S...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) sats it has received approval from the US FDA to proceed wi...
Read ArticleThe S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBKD) is down 2.7% in the past yea...
Read ArticleNeuren Pharmaceuticals (NEU) receives approval from the US Food and Drug Administration to proceed...
Read ArticleHighlights Despite the ASX 200 trading on an uncertain note in the recent past, some stocks hav...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power,who has been a senior analyst with Morgans Financial...
Read ArticleASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 bein...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price has more than doubled in less than a month....
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleWhile the S&P/ASX 200 Index (ASX: XJO) hasn’t provided much of a Santa rally this year, there a...
Read ArticleShareholders of Dimerix (ASX:DXB) got an early Christmas present with the company telling them its P...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThere were few major catalysts on Thursday, as the ASX traded flat in a relatively cruisy session fo...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleRett Syndrome is a rare genetic neurological disorder that affects the way the brain develops, causi...
Read ArticleThe ASX finished 0.67% higher, marking the best performance by the Australian bourse since early Oct...
Read ArticleThe share market climbed for a third day, adding to gains after the Reserve Bank appeared to open th...
Read ArticleHighlights Newly listed companyRocketBoots declined as much as 17.5% on ASX debut. Zip Co surge...
Read ArticleHighlights The ASX 200 traded higher by 0.6% by mid-session on Tuesday. Barring utilities and m...
Read ArticleNeuren Pharmaceuticals’ (NEU) partner has announced positive top-line results from a phase three st...
Read ArticleThe share market climbed to its highest in a week before tempering gains ahead of this afternoon’s R...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price is soaring to yearly highs on the back of pos...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader inde...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has reported that its partner for trofinetide in North Amer...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleNeuren Pharmaceuticals (NEU) releases its September quarterly report, highlighting the progress wit...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced it has received a Notice of Allowance from th...
Read ArticleNeuren Pharmaceuticals (NEU) receives a Notice of Allowance from the US Patent and Trademark Office...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has raised $20 million through a placement of new shares to...
Read ArticleASX Capital Raise Roundup is a fortnightly look at ASX capital raisings. Investors were taken by sur...
Read ArticleBankers for clinical-stage biotech company Neuren Pharmaceuticals will be pounding the virtual pavem...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has granted Orphan Drug desig...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) today reported that its US partner for trofinetide, Acadia...
Read ArticleHighlights ASX-listed healthcare companies rarely fail to bring joy to the market participants,...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleSummary Emyria has signed a deal with the University of Western Australia (UWA) to develop a nov...
Read ArticleSummary Decmil (ASX:DCG) receives A$21 million civil balance of plant works contract dorsaVi (...
Read ArticleASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which ro...
Read ArticleNeuren Pharmaceuticals (ASX: NEU) today announced that its US partner Acadia Pharmaceuticals...
Read ArticleWall Street mixed on Fed’s statement US stock markets were mixed overnight, after the US Fed Vice Ch...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleOver the past month, a number of US FDA approvals have moved the share prices of global pharma stock...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHighlights: Clear and constructive guidance received from pre-IND meetings with the FDA Office of...
Read ArticleThe USA is the world’s largest healthcare market and therefore a dream for ASX health stocks to ente...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) says it has received "clear and constructive guidance" from...
Read ArticleSummary Neuren Pharmaceuticals obtained a Canadian patent grant for trofinetide, with a patent t...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has announced that manufacturing of the drug substance for...
Read ArticleSource:Master Video, Shutterstock Summary Neuren Pharmaceuticals updated the market that drug m...
Read ArticleNeuren Pharmaceuticals Ltd (ASX: NEU) shares are trending higher in early afternoon trade. This com...
Read ArticleWhat sounds more appealing for investors: a billion-dollar blockbuster drug with mass market appeal,...
Read ArticleAustralian biotechnology company Neuren Pharmaceuticals (ASX:NEU) has reported a phase one t...
Read ArticleInvex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use...
Read ArticleThe company is developing new therapies to treat serious neurological disorders that emerge in early...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price has changed direction today despite positive...
Read Article“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Austral...
Read ArticleMelbourne-based company Neuren Pharmaceuticals (ASX:NEU) says it has initiated the manufactu...
Read ArticleThe sudden drop in spot gold prices and reintroduction of COVID-19 restrictions in New Zealand have...
Read ArticleASX companies continued to raise money in July, with over $4bn shelled out by investors, taking 2020...
Read ArticleCancer therapeutics biotech Immutep (ASX:IMM) has enrolled and dosed the last patient for a segment...
Read ArticleBiotechnology outfit Neuren Pharmaceuticals was fronting funds on Thursday morning.
Read ArticleFortunes were to be made in ASX health stocks during March and April as investors looked for salvati...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read Article27 May 2020 - Neuren Pharmaceuticals (ASX:NEU) today announced the appointment of Jon Pilcher and Pa...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleWhile we need all the bacteria fighters we can get right now, they are not immune to the coronovirus...
Read ArticleNeuren Pharmaceuticals (ASX: NEU) is getting interesting results from a mouse trial of a treatment f...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price has dropped lower with the market on Friday...
Read ArticleTrofinetide is an investigational drug developed by Neuren designed to treat the core symptoms of Re...
Read Article04 Mar 2020 - Acadia Pharmaceuticals Inc. and Neuren Pharmaceuticals (ASX:NEU) announced today that...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has been granted Rare Pediatric Disease (RPD) designation for its R...
Read ArticleDrug development is an extensive process and includes drug discovery & development, pre-clinical...
Read ArticleAustralian health care sector is booming with strong growth prospects amid global trade worries and...
Read ArticleIt can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve smal...
Read ArticleAustralia’s health care industry is one of the fastest growing industries in the country that is mak...
Read ArticleDrug Development Process The drug development process starts from drug discovery and ends at the lau...
Read ArticleOne of the oldest tropes in journalism is the miracle cure. Startup Daily is old enough to remember...
Read ArticleThere are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so...
Read ArticleHealth care system of Australia is considered as one of the best, globally, as it delivers safe and...
Read ArticleHealth stocks are reckoned amid those that can rapidly grow from a single line of product with small...
Read ArticleAustralian health care sector is growing potentially by generating significant profits in a short pe...
Read ArticleStrong gains among selected life science shares is fuelling optimism the sector may have further to...
Read ArticleA drug developed by Neuren Pharmaceuticals (ASX: NEU) to treat debilitating childhood neurodevelopme...
Read ArticleThe Federal agency of the United States Department of Health and Human Services, US Food and Drug Ad...
Read ArticleAgri-tech business Roots Sustainable Agricultural Technologies (ASX:ROO) says its crop-cooling techn...
Read ArticleUS Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren Pharmaceuticals’...
Read ArticleThe S&P/ASX 200 index looks set to finish the week on a high on Friday. In afternoon trade the...
Read ArticleEven though the stock markets are sensitive to the global macro-economic parameters, in the present...
Read ArticleHealthcare Healthcare sector comprises of the companies that offer medical services, producing medi...
Read ArticleIn the never-ending battle against bacteria, Next Science (ASX:NSX) has adopted a ‘take no prisoners...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
